Advertisement

CardioVascular and Interventional Radiology

, Volume 36, Issue 6, pp 1452–1463 | Cite as

Prostatic Artery Embolization for Enlarged Prostates Due to Benign Prostatic Hyperplasia. How I Do It

  • Francisco C. CarnevaleEmail author
  • Alberto A. Antunes
Review/State of the Art

Abstract

Prostatic artery embolization (PAE) has emerged as an alternative to surgical treatments for benign prostatic hyperplasia (BPH). Patient selection and refined technique are essential for good results. Urodynamic evaluation and magnetic resonance imaging are very important and technical limitations are related to elderly patients with tortuous and atherosclerotic vessels, anatomical variations, difficulty visualizing and catheterizing small diameter arteries feeding the prostate, and the potential risk of bladder and rectum ischemia. The use of small-diameter hydrophilic microcatheters is mandatory. Patients can be treated safely by PAE with low rates of side effects, reducing prostate volume with clinical symptoms and quality of life improvement without urinary incontinence, ejaculatory disorders, or erectile dysfunction. A multidisciplinary approach with urologists and interventional radiologists is essential to achieve better results.

Keywords

Benign prostatic hyperplasia Prostatic artery embolization Cone-beam CT and LUTS 

Notes

Acknowledgments

The authors thank Joaquim Mauricio da Motta-Leal-Filho, Eduardo Muracca Yoshinaga, Vanessa Cristina de Paula Rodrigues, Airton Mota Moreira, Octavio Meneghelli Galvão Gonçalves, Andre Moreira de Assis, Ronaldo Hueb Baroni, Antonio Sergio Zafred Marcelino, Luciana Mendes de Oliveira Cerri, Miguel Srougi and Giovanni Guido Cerri for their important collaboration.

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Wei JT, Calhoun E, Jacobsen SJ (2005) Urologic disease in America project: benign prostatic hyperplasia. J Urol 173(4):1256–1261PubMedCrossRefGoogle Scholar
  2. 2.
    Emberton M, Andriole GL, de la Rosette J et al (2003) Benign prostatic hyperplasia. A progressive disease of aging men. Urology 61:267–273PubMedCrossRefGoogle Scholar
  3. 3.
    Ziada A, Rosenblum M, Crawford ED (1999) Benign prostatic hyperplasia: an overview. Urology 53:1–6PubMedCrossRefGoogle Scholar
  4. 4.
    AUA Practice Guidelines Committee (2003) AUA guideline on management of benign prostatic hyperplasia. I. Diagnosis and treatment recommendations. J Urol 170:530–547CrossRefGoogle Scholar
  5. 5.
    Bramson H, Hermann D, Batchelor K et al (1997) Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther 282:1496PubMedGoogle Scholar
  6. 6.
    Kramer B, Hagerty K, Justman S et al (2009) Use of 5-α-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline Summary. J Clin Oncol 27:1502PubMedCrossRefGoogle Scholar
  7. 7.
    Pareek G, Shevchuk M, Armenakas N et al (2003) The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol 169:20PubMedCrossRefGoogle Scholar
  8. 8.
    Canda AE, Mungan MU, Yilmaz O et al (2006) Effects of finasteride on the vascular surface density, number of microvessels and vascular endothelial growth factor expression of the rat prostate. Int Urol Nephrol 38:275PubMedCrossRefGoogle Scholar
  9. 9.
    Kaplan SA (2005) Factors in predicting failure with medical therapy for BPH. Rev Urol 7(Suppl 7):S34–S39Google Scholar
  10. 10.
    McVary KT (2006) BPH: epidemiology and comorbidities. Am J Manage Care 12(5 Suppl):S122–S128Google Scholar
  11. 11.
    Chute CG, Panser LA, Girman CJ et al (1993) The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 150:85–89PubMedGoogle Scholar
  12. 12.
    Rubenstein J, McVary KT (2003) Transurethral microwave thermotherapy for benign prostatic hyperplasia. Int Braz J Urol 29:251–263Google Scholar
  13. 13.
    Muruve NA, Steinbecker K (2010) Transurethral needle ablation of the prostate (TUNA). http://emedicine.medscape.com/article/ 449477-overview
  14. 14.
    Appleton DS, Sibley GN, Doyle PT (1988) Internal iliac artery embolisation for the control of severe bladder and prostate haemorrhage. Br J Urol 61:45–47PubMedCrossRefGoogle Scholar
  15. 15.
    Michel F, Dubruille T, Cercueil JP (2002) Arterial embolization for massive hematuria following transurethral prostatectomy. J Urol 168:2550–2551PubMedCrossRefGoogle Scholar
  16. 16.
    Rastinehad AR, Caplin DM, Ost MC et al (2008) Selective arterial prostatic embolization (SAPE) for refractory hematuria of prostatic origin. Urology 71:181–184PubMedCrossRefGoogle Scholar
  17. 17.
    DeMeritt JS, Elmasri FF, Esposito MP et al (2000) Relief of benign prostatic hyperplasia-related bladder outlet obstruction after transarterial polyvinyl alcohol prostate embolization. J Vasc Interv Radiol 11:700–767CrossRefGoogle Scholar
  18. 18.
    Carnevale FC, Antunes AA, da Motta Leal Filho JM et al (2010) Prostatic artery embolization as a primary treatment for benign prostatic hyperplasia: preliminary results in two patients. Cardiovasc Intervent Radiol 33:355–361PubMedCrossRefGoogle Scholar
  19. 19.
    Carnevale FC, da Motta-Leal-Filho JM, Antunes AA et al (2011) Midterm follow-up after prostate embolization in two patients with benign prostatic hyperplasia. Cardiovasc Intervent Radiol 34:1330–1333PubMedCrossRefGoogle Scholar
  20. 20.
    Pisco JM, Pinheiro LC, Bilhim T et al (2011) Prostatic arterial embolization to treat benign prostatic hyperplasia. J Vasc Interv Radiol 22(1):11–19PubMedCrossRefGoogle Scholar
  21. 21.
    Schafer W, Abrams P, Liao LM et al (2002) Good urodynamic practices: uroflowmetry, filling cystometry, and pressure flow studies. Neurourol Urodyn 21:261–274PubMedCrossRefGoogle Scholar
  22. 22.
    Abrams P (1999) Bladder outlet obstruction index, bladder contractility index and bladder voiding efficiency: three simple indices to define bladder voiding function. BJU Int 84(1):14–15PubMedCrossRefGoogle Scholar
  23. 23.
    Clegg EJ (1955) The arterial supply of the human prostate and seminal vesicles. J Anat 89:209–216PubMedGoogle Scholar
  24. 24.
    Bilhim T, Pisco JM, Furtado A et al (2011) Prostatic arterial supply: demonstration by multirow detector angio CT and catheter angiography. Eur Radiol 21(5):1119–1126PubMedCrossRefGoogle Scholar
  25. 25.
    Carnevale FC, da Motta-Leal-Filho JM, Antunes AA et al (2013) Quality of life and clinical symptoms improvement support prostatic artery embolization for patients with acute urinary retention due to benign prostatic hyperplasia. J Vasc Interv Radiol 24(4):535–542PubMedCrossRefGoogle Scholar
  26. 26.
    National Cancer Institute (2009) Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0 Published: May 28, 2009 (V4.03: June 14, 2010) U.S. Department of Health and Human Services National Institute of Health (NIH) Publication no. 09-5410. http://evs.nci.nih.gov/Ftp1/CTCAE/Abont.html. Accessed 16 May 2013
  27. 27.
    Antunes AA, Carnevale FC, da Motta-Leal-Filho JM et al (2013) Clinical, laboratorial and urodynamic findings of prostatic artery embolization for the treatment of urinary retention related to benign prostatic hyperplasia: a prospective single center pilot study. Cardiovasc Intervent Radiol 36(4):978–986Google Scholar

Copyright information

© Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2013

Authors and Affiliations

  1. 1.Interventional Radiology UnitUniversity of Sao Paulo Medical SchoolSão PauloBrazil
  2. 2.Division of UrologyUniversity of Sao Paulo Medical SchoolSão PauloBrazil
  3. 3.São PauloBrazil

Personalised recommendations